Anabel Costa-Ferreira

Anabel Costa-Ferreira

Reporter

Anabel is a Reporter, working across the six Citeline publications. She is a recent graduate from the University of Exeter and holds a BA English degree. Since graduating, Anabel has also completed an editorial internship with the In Vivo team. Before joining Norstella she spent the past year as Editor-in-Chief of her university’s student paper, Exeposé, managing an editorial team to produce a 32-page paper on a fortnightly basis.

Latest from Anabel Costa-Ferreira

Podcast: JPM Tracked And Unpacked

In the latest episode of the In Vivo podcast, Citeline’s expert panel of reporters and analysts unpack the biggest deals, trends and innovations following the J.P. Morgan Healthcare Conference.

Swissmedic Says No Room for Misleading Claims Amid Media Clash Over Weight-Loss Drugs

Recent court cases initiated by the Swiss medicines regulator against “unbalanced” media reporting on GLP-1 drugs for weight loss highlights its zero tolerance for any form of misinformation that compromises patient safety.

Global Pharma Guidance Tracker – January 2025

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

WHO Issues Environmental Sustainability Call To Regulators And Pharmaceutical Industry

The World Health Organization (WHO) has launched an initiative to highlight the pressing global need to reduce the impact of the pharmaceutical industry on the environment while maintaining high standards of safety and efficacy for products.

Quotable: Top Experts On Policy Hot Topics

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.

EU Public-Private Partnership Invests €66.8M To ‘Transform Clinical Studies’ By Boosting Diversity

A six-year project aiming to establish a “less fragmented and more democratic” approach to clinical studies has commenced in the EU.